Patents by Inventor Zheng-Yu Yang

Zheng-Yu Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20240376110
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: May 14, 2024
    Publication date: November 14, 2024
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Yifan Deng, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Benjamin J. June, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Katie A. Spence, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 12121511
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 12091404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 17, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • HIV inhibitor compounds
    Patent number: 12084455
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Thiadiazole IRAK4 inhibitors
    Patent number: 12060351
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20240254118
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: December 20, 2023
    Publication date: August 1, 2024
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Michael L. Mitchell, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Zheng-Yu Yang
  • Pentacyclic derivatives as Zika virus inhibitors
    Patent number: 12037340
    Abstract: Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: July 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elbert Chin, John O. Link, James G. Taylor, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20240199580
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: November 6, 2023
    Publication date: June 20, 2024
    Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20240199589
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: October 27, 2023
    Publication date: June 20, 2024
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 11858918
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 2, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 11851419
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: December 26, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230391747
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 7, 2023
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
    Publication number: 20230257386
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.
    Type: Application
    Filed: November 23, 2022
    Publication date: August 17, 2023
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas J. Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn S. Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Thiadiazole IRAK4 inhibitors
    Patent number: 11702414
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • GLP-1R modulating compounds
    Patent number: 11702404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230102927
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: March 30, 2023
    Applicants: Gilead Sciences, Inc., Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Pyrrolo[1,2-b]pyridazine derivatives
    Patent number: 11572362
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230021705
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: January 26, 2023
    Inventors: Megan K. Armstrong, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Chao-I Hung, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • HIV INHIBITOR COMPOUNDS
    Publication number: 20230027055
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: April 7, 2021
    Publication date: January 26, 2023
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS
    Publication number: 20220411434
    Abstract: Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein,
    Type: Application
    Filed: May 19, 2022
    Publication date: December 29, 2022
    Inventors: Elbert Chin, John O. Link, James G. Taylor, Zheng-Yu Yang